514 related articles for article (PubMed ID: 19948947)
1. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
Farid NA; Kurihara A; Wrighton SA
J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
[TBL] [Abstract][Full Text] [Related]
2. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
Hagihara K; Kazui M; Kurihara A; Yoshiike M; Honda K; Okazaki O; Farid NA; Ikeda T
Drug Metab Dispos; 2009 Nov; 37(11):2145-52. PubMed ID: 19704027
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
Abell LM; Liu EC
J Pharmacol Exp Ther; 2011 Nov; 339(2):589-96. PubMed ID: 21828263
[TBL] [Abstract][Full Text] [Related]
4. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
5. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
[TBL] [Abstract][Full Text] [Related]
6. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL
Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918
[TBL] [Abstract][Full Text] [Related]
8. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Takahashi M; Kurihara A; Okazaki O; Farid NA; Ikeda T
Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
[TBL] [Abstract][Full Text] [Related]
9. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the metabolism of clopidogrel and prasugrel.
Laizure SC; Parker RB
Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1417-24. PubMed ID: 20839914
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
[TBL] [Abstract][Full Text] [Related]
13. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
Wynn RL
Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
[No Abstract] [Full Text] [Related]
14. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
15. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
[TBL] [Abstract][Full Text] [Related]
16. Metabolic differences of current thienopyridine antiplatelet agents.
Fareed J; Jeske W; Thethi I
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):307-17. PubMed ID: 23289968
[TBL] [Abstract][Full Text] [Related]
17. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Tantry US; Jeong YH; Navarese EP; Kubica J; Gurbel PA
Expert Rev Cardiovasc Ther; 2013 Apr; 11(4):447-62. PubMed ID: 23570358
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS
Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
